(NASDAQ: DVAX) Dynavax Technologies's forecast annual revenue growth rate of 17.14% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 35.74%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.59%.
Dynavax Technologies's revenue in 2026 is $330,514,000.On average, 5 Wall Street analysts forecast DVAX's revenue for 2026 to be $47,001,691,941, with the lowest DVAX revenue forecast at $41,443,968,206, and the highest DVAX revenue forecast at $51,429,787,485. On average, 5 Wall Street analysts forecast DVAX's revenue for 2027 to be $54,058,932,518, with the lowest DVAX revenue forecast at $46,182,065,665, and the highest DVAX revenue forecast at $60,750,981,444.
In 2028, DVAX is forecast to generate $62,706,107,162 in revenue, with the lowest revenue forecast at $59,264,381,350 and the highest revenue forecast at $65,602,981,122.